CRIS missed EPS expectations by 18.94%
Aug 01, 2024, 12:36 PM
0.00%
What does CRIS do
Curis Inc, based in Lexington, Massachusetts, specializes in biotechnology, focusing on developing cancer therapies, including its lead drug, Emavusertib, which targets IRAK4 kinase. Established in 2000 and employing 51 people, Curis also has other programs like Erivedge, which inhibits the Hedgehog signaling pathway, and CI-8993 targeting VISTA protein.
Curis (CRIS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Curis's actual EPS was -$2.03, missing the estimate of -$1.71 per share, resulting in a -18.94% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.